Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced stage cancer~* First episode of malignant ascites~* Grade 2 or 3 ascites~* Clinically symptomatic ascites requiring paracentesis due to : abdominal pain or heaviness, dyspnoea, orthopnoea, nausea/vomiting, anorexia, early satiety, gastro-oesophageal reflux, lower limb and genital oedema~* Age ≥ 18 years~* Performance status ≤ 3~* Life expectancy ≥ 1 month~* Absence of contra-indication to diuretic treatment~* Patient regularly followed up by a palliative care or supportive care team~* Signed and dated informed consent~Exclusion Criteria:~* Hepatic disorders : cirrhosis, hepatitis, hepatocellular insufficiency, hepatic encephalopathy~* Non malignant ascites~* Hydroelectrolytic disorders: hyponatremia (\< 130 mmol/L) or hyperkaliemia (\> 5 mmol/L) or severe hypokaliemia (\< 3 mmol/L)~* Functional acute renal insufficiency~* Urinary disorders : Obstruction in the urinary tract, Oliguria/anuria~* Chronic renal failure~* Patient unable to swallow~* Sulfamides allergy~* Hypersensitivity to spironolactone or to any of the excipients~* Hypersensitivity to furosemide or to any of the excipients~* Pregnant or breastfeeding women~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A : observation (Type: NO_INTERVENTION): Clinical monitoring and best supportive care.
- B : diuretics (Type: ACTIVE_COMPARATOR): Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).